The support of human genetic evidence for approved drug indications-Reference-Cited by-同舟云学术

The support of human genetic evidence for approved drug indications

Published:2015-06-29 Issue:8 Volume:47 Page:856-860
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Nelson Matthew R,Tipney Hannah,Painter Jeffery L,Shen Judong,Nicoletti Paola,Shen Yufeng,Floratos Aris,Sham Pak Chung,Li Mulin Jun,Wang Junwen,Cardon Lon R,Whittaker John C,Sanseau Philippe

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng.3314.pdf

Reference24 articles.

1. DiMasi, J.A., Feldman, L., Seckler, A. & Wilson, A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87, 272–277 (2010).

2. Arrowsmith, J. & Miller, P. Trial watch: phase II and phase III attrition rates 2011–2012. Nat. Rev. Drug Discov. 12, 569 (2013).

3. Cook, D. et al. Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014).

4. Morgan, P. et al. Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival. Drug Discov. Today 17, 419–424 (2012).

5. Welter, D. et al. The NHGRI GWAS Catalog, a curated resource of SNP-trait associations. Nucleic Acids Res. 42, D1001–D1006 (2014).

Cited by 1213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. GETdb: A comprehensive database for genetic and evolutionary features of drug targets;Computational and Structural Biotechnology Journal;2024-12

2. Identifying genetic determinants of sarcopenia-related traits: a Mendelian randomization study of druggable genes;Metabolism;2024-11

3. Artificial intelligence with mass spectrometry-based multimodal molecular profiling methods for advancing therapeutic discovery of infectious diseases;Pharmacology & Therapeutics;2024-11

4. Identification of potential drug targets for amyotrophic lateral sclerosis by Mendelian randomization analysis based on brain and plasma proteomics;Experimental Gerontology;2024-10

5. Integrating genetic and proteomic data to elucidate the association between immune system and blood-brain barrier dysfunction with multiple sclerosis risk and severity;Journal of Affective Disorders;2024-10